INTRODUCCIÓN: REVISIÓN CRITICA DEL PROBLEMA

REFERENCIAS BIBLIOGRÁFICAS
74. Cohen MP. Intervention strategies to prevent pathogenetic effects of glycated albumin. Arch
Biochem Biophys. 2003 Nov 1;419(1):25-30..
75. Smith PR, Thornalley PJ. Mechanism of the degradation of nonenzymatically glycated
proteins under physiological conditions. Studieswith the model fructosamine, N epsilon-
(1-deoxy-D-fructos-1-yl)hippuryl-lysine. Eur J Biochem. 1992 Dec 15;210(3):729-39.
76. Schalkwijk CG, Miyata T. Early- and advanced non-enzymaticglycation in diabetic vascular
complications: the search for therapeutics. Amino Acids. 2010 Oct 20.
77. Koga M, Kasayama S. Clinical impact of glycated albumin as another glycemic control
marker. Endocr J. 2010;57(9):751-62..
78. Shaklai N, Garlick RL, Bunn HF. Nonenzymatic glycosylation of human serum albumin alters
its conformation and function. J Biol Chem. 1984 Mar 25;259(6):3812-7.
79. Chen S, Cohen MP, Ziyadeh FN. Amadori-glycated albumin in diabetic nephropathy:
pathophysiologic connections. Kidney Int Suppl. 2000 Sep;77:S40-4.
80. Cohen MP, Chen S, Ziyadeh FN, Shea E, Hud EA, Lautenslager GT, Shearman CW.
Evidence linking glycated albumin to altered glomerular nephrin and VEGF expression,
proteinuria, and diabetic nephropathy. Kidney Int. 2005 Oct;68(4):1554-61.
81. Furusyo N, Koga T, Ai M, Otokozawa S, Kohzuma T, Ikezaki H, Schaefer EJ, Hayashi J.
Utility of glycated albumin for the diagnosis of diabetes mellitus in a Japanese population
study: results from the Kyushu and Okinawa Population Study (KOPS). Diabetologia.
2011 Dec;54(12):3028-36.
82. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes
Care. 2010 Jan;33 Suppl 1:S62-9.
83. Zhang Q, Ames JM, Smith RD, Baynes JW, Metz TO.A perspective on the Maillard reaction
and the analysis of protein glycation by mass spectrometry: probing the pathogenesis of
chronic disease. J Proteome Res. 2009 Feb;8(2):754-69.
84. Moriyama T, Kemi M, Okumura C, Yoshihara K, Horie T. Involvement of advanced glycation
end-products, pentosidine and N(epsilon)-(carboxymethyl)lysine, in doxorubicin-induced
cardiomyopathy in rats. Toxicology. 2010 Jan 31;268(1-2):89-97.
85. Brownlee M, Cerami A, Vlassara H. Advanced glycosylation end products in tissue and the
biochemical basis of diabetic complications. N Engl J Med. 1988 May 19;318(20):1315-
21.
86. Miyata T, Wada Y, Cai Z, Iida Y, Horie K, Yasuda Y, Maeda K, Kurokawa K, van Ypersele de
Strihou C. Implication of an increased oxidative stress in the formation of advanced
glycation end products in patients with end-stage renal failure. Kidney Int. 1997
Apr;51(4):1170-81.
87. Bansal S, Siddarth M, Chawla D, Banerjee BD, Madhu SV, Tripathi AK. Advanced glycation
end products enhance reactive oxygen and nitrogen species generation in neutrophils in
vitro. Mol Cell Biochem. 2011 Nov 3.
88. Li Y, Wang S. Glycated albumin activates NADPH oxidase in rat mesangial cells through upregulation
of p47phox. Biochem Biophys Res Commun. 2010 Jun 18;397(1):5-11.
89. Su J, Lucchesi PA, Gonzalez-Villalobos RA, Palen DI, Rezk BM, Suzuki Y, Boulares HA,
Matrougui K. Role of advanced glycation end products with oxidative stress in resistance
artery dysfunction in type 2 diabetic mice. Arterioscler Thromb Vasc Biol. 2008
Aug;28(8):1432-8.
90. Cárdenas-León M, Díaz-Díaz E, Argüelles-Medina R, Sánchez-Canales P, Díaz-Sánchez V,
Larrea F.Glycation and protein crosslinking in the diabetes and ageing pathogenesis. Rev
Invest Clin. 2009 Nov-Dec;61(6):505-20.
91. Brownlee M. The pathological implications of protein glycation. Clin Invest Med. 1995
Aug;18(4):275-81.
92. Ulrich P, Cerami A. Protein glycation, diabetes, and aging. Recent Prog Horm Res.
2001;56:1-21.
229